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Our knowledge of disease genes in neurological dis-
orders is incomplete.With the aimof closing this gap,
we performed whole-exome sequencing on 143
multiplex consanguineous families in whom known
disease genes had been excluded by autozygosity
mapping and candidate gene analysis. This pre-
screening step led to the identification of 69 reces-
sive genes not previously associated with disease,
of which 33 are here described (SPDL1, TUBA3E,
INO80, NID1, TSEN15, DMBX1, CLHC1, C12orf4,
WDR93, ST7, MATN4, SEC24D, PCDHB4, PTPN23,
TAF6, TBCK, FAM177A1, KIAA1109, MTSS1L,148 Cell Reports 10, 148–161, January 13, 2015 ª2015 The AuthorsXIRP1, KCTD3, CHAF1B, ARV1, ISCA2, PTRH2,
GEMIN4, MYOCD, PDPR, DPH1, NUP107, TMEM92,
EPB41L4A, and FAM120AOS). We also encountered
instances in which the phenotype departed signifi-
cantly from the established clinical presentation of
a known disease gene. Overall, a likely causal muta-
tion was identified in >73% of our cases. This study
contributes to the global effort toward a full compen-
dium of disease genes affecting brain function.
INTRODUCTION
Neurogenetic disorders represent the largest category of Men-
delian diseases in humans. They encompass a wide array of
clinical presentations that range from the common e.g., intellec-
tual disability (>1%) to the very rare, e.g., neurodegeneration
with brain iron accumulation (one to three per 106) (Kalman
et al., 2012;Maulik et al., 2011). The highly prevalent involvement
of the nervous system in many Mendelian disorders coincides
with the observation that >80% of all human genes are ex-
pressed at some stage of brain development (Hawrylycz et al.,
2012) and suggests that the brain is one of the most vulnerable
organs to genetic perturbation. In fact high-resolutionmicroarray
analysis of the human genome reveals that intellectual disability
is the common phenotypic denominator of genomic disorders
that involve losses or gains of genes (Coe et al., 2012).
Variances in clinical presentation are a major obstacle in
establishing a working molecular classification of neurological
disease, because even where the clinical presentation is highly
specific, genetic heterogeneity is the rule. In the setting of
autosomal recessive neurogenetic disorders where parents are
related, a homozygosity scan can serve as a guide to the under-
lying genetic cause even when the phenotype is atypical (Alkur-
aya, 2010). Another major challenge in assigning a molecular
classification is that many neurological disease genes have not
been identified yet.
Novel disease gene discovery in this field has been tremen-
dously abetted by next-generation sequencing, a tool with the
capacity to, theoretically, unravel the genetic cause of all neuro-
logical diseases. This full theoretical potential has not yet been
reached unfortunately, although the technology continues to
evolve. For example, two large studies on the genetics of intel-
lectual disability usingwhole-exome sequencing (WES) provided
a yield of 16%–55%, and even though the collective sample size
was >150, only seven novel genes were identified (de Ligt et al.,
2012; Rauch et al., 2012). In these studies, samples could not be
enriched for novel gene discovery, and simultaneously the antic-
ipatedmutations were heterozygous, detection of which poses a
challenge for the currently available sequencing technology
(especially regarding insertions/deletions) (Harismendy et al.,
2009). The presence of these two obstacles likely hindered the
authors’ ability to obtain a higher yield. Thus, alternative/comple-
mentary approaches are required to facilitate the discovery of
novel neurogenetic disease genes. In this study, we show that
the analysis of the entire set of autozygous intervals per individ-
ual (the autozygome) in multiplex consanguineous patients, as a
prescreen, can markedly increase the yield of WES to identify
candidate genes not previously associated with disease. Even
when known genes were identified using this approach, the
phenotype was often sufficiently different to explain why the
gene had been missed by the autozygosity filter. The 33 candi-
date disease genes we showcase in this study will augment
the global hunt for the genetics of brain development and
function.
RESULTS
Clinical Report
In total, 143 multiplex families met our inclusion criteria (a neuro-
genetic diagnosis, positive family history, consanguineous
parents, and no candidates identified by autozygosity mapping).
Intellectual disability was the most common clinical feature.COther phenotypes that were also enriched included global
developmental delay, autism, epilepsy, primary microcephaly,
ataxia, and neurodegeneration. Table S1 summarizes the clinical
features of the entire cohort.
Autozygosity Mapping Is a Powerful Enrichment Tool for
Novel Candidate Gene Discovery
As a prescreening step for each case, the regions of homozygos-
ity (ROH), the telltale sign of shared ancestral haplotypes, were
interrogated for disease genes that matched the patients’
phenotype. These genes were prioritized for Sanger sequencing.
If negative, or when no compelling disease genes were evident in
the ROH, patient DNAwas subjected toWES under the assump-
tion that this will reveal a novel disease gene. This assumption
fails, however, to account for certain scenarios. When disease
genes within the ROH are examined for a likely candidate, it is
possible that the clinical picture may sufficiently deviate from
the classical phenotype ascribed to a particular gene such that
the gene falls outside our consideration. Specifically, we list in
Table 1 cases in which there was sufficient discrepancy between
the classical and observed phenotypes that the respective
genes were missed in the autozygosity mapping stage. Some
phenotypes can even be considered unique rather than an
expansion of a known phenotype.
A second reason why WES may reveal a known disease gene
is that the causal mutation may lie within an ROH but fail to be
detected, which is one of the known ‘‘pitfalls’’ of autozygosity
mapping (Alkuraya, 2012). Figure S1 captures the homozygosity
pattern of a number of patients for whom the candidate ROHwas
missed, because it did not meet our ROH size cutoff, or it ap-
peared to be shared by an unaffected member of the family, or
the overlap of the gene with the ROHwas not clearly discernible.
One case (11DG0165) evaded detection due to the presence of
a deep intronic mutation, which was later uncovered using RT-
PCR. A third scenario for whyWESmay expose a known disease
gene is that the gene was simply overlooked when searching for
plausible candidates within an ROH. This occurred in 13DG1803
where TUSC3, a known intellectual disability gene, was not
noticed during the prescreening stage. Further scenarios include
incomplete clinical information at the time of analysis (as
occurred with 09DG-00774 and 12DG0926) and poor descrip-
tion in the literature (discussed below). We emphasize, however,
that cases of failed autozygosity map prescreening are the
exception rather than the rule because they represent only
7.7% (11/143) of all cases and have reduced the hypothetical
yield of WES in revealing candidate genes not associated with
disease, or known genes with unique phenotypes, by only 2.2%.
WES Is a Powerful Novel Candidate GeneDiscovery Tool
in Neurogenetic Disorders
Consistent with our prescreening enrichment step, WES re-
vealed 69 genes that were not known to the authors at the
time of exome capture. Of these, 36 have since been published
by either us or others (detailed in Table S1), leaving 33 candidate
genes that are here reported. The phenotypes associated with
these are described in Table 2 and include intellectual disability,
autism, progressive cerebellar atrophy, primary microcephaly,
brain atrophy and other malformations, and myopathy. Of theseell Reports 10, 148–161, January 13, 2015 ª2015 The Authors 149
Table 1. Cases with Mutations in Known Disease Genes following WES, Where the Patient Phenotype Diverged from the Established Literature
ID Gene Mutation Published Phenotype Observed Phenotype Reference
09DG0057 GM2A NM_000405.4:c.164C > T:p.P55L GM2-gangliosidosis,
AB variant
progressive neurodegeneration with
onset at 8 years, no organomegaly
and normal retina
this study
12DG0096 SPG20 NM_001142294:c.1450_1451insA:p.T484fs spastic paraplegia speech and motor delay, tremor,
microcephaly, and strabismus
this study
12DG1571 CYP27A1 NM_000784:c.1342C > T:p.R448C cerebrotendinous
xanthomatosis
severe choreoathetosis, no cataract,
and normal cholestanol
this study
10DG0672 NPC2 NM_006432:c.88G > A: p.V30M Nieman-Pick disease microcephaly, static encephalopathy,
no organomegaly, and normal retina
this study
11DG1951 ARFGEF2 NM_006420:c.656_657insC:p.P219fs periventricular heterotopia
with microcephaly
global developmental delay, epilepsy,
and hydrocephalus
this study
11DG1510 PNKP NM_007254:c.1250_1251insAACGGGTCGCCATCGAC:p.R418Tfs*55 progressive microcephaly,
infantile-onset seizures,
and developmental delay
primary microcephaly, global
developmental delay, no seizures
this study
12DG0975 RYR1 NM_000540:c.6617C > T:p.T2206M minicore myopathy ptosis, no motor delay, and sacral
agenesis
this study
12DG0104 FBN2 NM_001999:c.1064G > A:p.G355D congenital contractural
arachnodactyly
fetal akinesia with brain ischemia and
neonatal death
this study
08DG00385 BRCA2 NM_000059.3:c.9152 delC:p.P3051Hfs*11 Fanconi anemia primordial dwarfism Shaheen
et al. (2014)
10DG1721 EVC2 NM_147127.4:c.3870_3893 dup:p.K1293_K1300 dup Ellis-van-Creveld syndrome Meckel-Gruber syndrome Shaheen
et al. (2013)
13DG0583 DDHD2 NM_015214.2:c.1249_1891 del:p.A417Mfs*23 (large scale deletion) spastic paraplegia isolated cerebellar atrophy this study
13DG0010 WDR81 NM_001163809:c.845G > A:p.G282E cerebellar ataxia, mental
retardation, and dysequilibrium
syndrome-2
neonatal death due to severe brain
malformation (hydranencephaly and
severe cerebellar hypoplasia)
this study
12DG0685 ZNF526 NM_133444:c.479A > C:p.K160T nonsyndromic intellectual
disability
intellectual disability, Noonan-like
facies, and pulmonary stenosis
this study
09DG00930 ADCK3 NM_020247:c.1744 dup:p.S582Kfs*148 cerebellar ataxia, seizure and
cerebellar atrophy
isolated cerebellar hypoplasia this study
09DG0301 SBF1 NM_002972:c.1327G > A:p.D443N Charcot-Marie-Tooth disease
type 4B3
Charcot-Marie-Tooth with microcephaly,
ophthalmoplegia and syndactyly
Alazami
et al. (2014)
11DG1767 AP4M1 NM_004722:c.C952T:p.R318* spastic paraplegia, severe ID,
poor speech development
microcephaly, speech delay, spasticity;
brain MRI: hypomyelination, hypoplastic
corpus callosum, and brain atrophy.
this study
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mutations, ten are truncating or located at splice sites. For the
missense changes, we determined pathogenicity based on the
in silico prediction of at least two established algorithms, as
well as 3D modeling of wild-type and mutant residues whenever
structure information on homologous proteins was available
(Figure S2). Our minimum threshold for assigning candidacy to
a gene was that the variant had to be the only one to survive
the stringent pipeline illustrated in Figure 2. A total of 37 cases
remain ‘‘unsolved,’’ some because more than one variant sur-
vived our filters. Table S1 lists these, and it is important to note
that some of these variants may indeed represent bona fide
novel disease genes.
In addition, WES revealed what appears to be phenotypes that
have not been described for the respective genes in 16 cases
(Table 1). One striking example is case 10DG0672 in which
we identified a previously reported homozygous mutation in
NPC2, a known gene for Nieman-Pick disease. Neither the index
nor his sibling had the typical presentation of progressive neuro-
degeneration or hepatosplenomegaly, thus making the diag-
nosis of Nieman-Pick nearly impossible on clinical grounds.
Finally, WES also revealed mutations in known genes for cases
with classical phenotypes, where the gene was missed either
due to a pitfall in autozygosity mapping or incomplete phenotyp-
ing (nine cases, discussed above) or because the phenotype
was not well described in the literature as in two instances.
The first such instance is MGAT2-related dysmorphism, which
had only been documented by a single photograph (Cormier-
Daire et al., 2000). The second instance involves CTSD, which
was described as causing congenital neuronal ceroid lipofusci-
nosis when, in fact, the detailed description of the case was
severe microlissencephaly and hyperekplexia, which is identical
to the phenotype of our case 09DG00288 (Fritchie et al., 2009).
Overall, the yield of WES in our cohort was 105 out of 143
(73.4%).
Although we used autozygosity mapping coupled with WES,
an alternative strategy is to simply use the mapping information
provided by WES analysis. Although most autozygous regions
can indeed be inferred by this second strategy, we had previ-
ously shown that the use of high-throughput genotyping results
in cleaner ROH data with sharper overall resolution (Carr et al.,
2013).
3D Modeling of Missense Variants to Support
Pathogenicity
3D modeling was performed for selected gene products using
the web-based homology modeling engine Phyre2 (Kelley and
Sternberg, 2009). Four of the models were built with very high
confidence and suggested a pathogenic nature for the identified
mutations. In the case of TUBA3E, the model was built based on
the structure of tubulin alpha-3E (PDB ID: 3EDL)(Tan et al., 2008)
that shares 97% sequence identity with the TUBA3E gene prod-
uct (Figure S2A). The R215Cmutation changes the charge distri-
bution on the surface of the protein. Although not participating
in microtubule formation (Tan et al., 2008), this site might be
involved in the binding of microtubule to other proteins or cofac-
tors. The structure of the gene product of TSEN15, human tRNA
splicing endonuclease, has been solved by nuclear magnetic
resonance (Song and Markley, 2007) (PDB ID: 2GW6). TheCconserved W76 is embedded inside the protein and is critical
in protein folding (Figure S2B). Mutation of W76G would leave
a void in the core of the protein and very likely lead to misfolded
proteins. PTRH2 encodes peptidyl-tRNA hydrolase 2. The crys-
tal structure of a domain of PTRH2 has been solved (PDB ID:
1QSR). The observed mutation at Q85 is located in the middle
of a helix and forms a hydrogen bond with the side chain of
T157 (Figure S2C). Mutation of Q85P would destabilize PTRH2
as it would disrupt the hydrogen bond. Furthermore, the muta-
tion to a prolinemay cause a kink in the helix and distort the over-
all fold of the structure. Iron-sulfur cluster assembly 2, or ISCA2,
was also modeled with the structure of its homolog of IscA from
Thermosynechococcus elongates (PDB ID: 1X0G), which is a
a2b2 heterotetramer. ISCA2 has modest sequence identity
(27% to PDB ID: 1X0G) to the a chain of the IscA. However,
Phyre2 predicted the same structural fold with 100% confi-
dence. The protein is involved in the maturation of iron-sulfur
proteins. According to the model, the G77S mutation occurs in
a loop that is directly involved in iron-sulfur cluster binding by
providing a chelating cysteine, C79 (Figure S2D). We speculate
that such a mutation might affect the stability or flexibility of
the loop and therefore interfere with its efficiency of binding to
the iron-sulfur cluster.
DISCUSSION
Several attempts have been made in the recent past to
accelerate the discovery of novel neurological disease genes.
One of the earliest attempts was the high-throughput Sanger
sequencing of all coding exons on the X chromosome in a large
cohort of >200 families with suspected X-linked intellectual
disability (Tarpey et al., 2009). In addition to the laborious nature
of this approach, the yield was somewhat modest (three novel
genes) partly because enrichment for novel gene discovery
was not feasible, and also partly due to a large proportion of
X-linked disease genes having already been established (de
Brouwer et al., 2007). High-resolution molecular karyotyping is
a powerful tool to identify a large number of DNA gains and los-
ses that are associated with various neurological phenotypes,
but the yield is typically <15%, and it rarely identifies single
genes due to the nature of the assay (Miller et al., 2010). Morrow
et al. used autozygosity mapping in nearly 90 consanguineous
families with autism, followed by Sanger sequencing of candi-
date genes within the linked ROH, to identify five novel autism
genes (Morrow et al., 2008). The lower yield of that study likely
originates from the use of conventional sequencing methods,
coupled with the potentially non-Mendelian behavior of autism
genes.
The advent of next-generation sequencing has revolutionized
the search for Mendelian neurocognitive genes. Rauch et al. and
de Ligt et al. studied >150 cases of intellectual disability using a
trio-exome design, and, although that approach is compatible
with identifying recessive disease genes, they only identified het-
erozygous de novo mutations, including seven novel genes (de
Ligt et al., 2012; Rauch et al., 2012). The known bias of current
WES against heterozygous mutations, especially insertions
and deletions, aswell as the inability of the investigators to enrich
their cohort for novel genes are likely explanations for the lowerell Reports 10, 148–161, January 13, 2015 ª2015 The Authors 151
Table 2. Cases with Mutations in Candidate Genes, along with Available Evidence from the Literature to Support Candidacy
ID Phenotype Gene Mutation
Mutation
Type Gene Description Supporting Evidence Reference
12DG1528 primary microcephaly
and neonatal death
CCDC99
(SPDL1)
NM_017785:c.1724_
1747 del:p.S575_T582
del
in-frame
deletion
spindle
apparatus
coiled-coil
protein 1
CCDC99 has been demonstrated
to control poleward movement of
chromosomes along the mitotic
spindles. Many primary
microcephaly genes encode
proteins that are involved in
mitotic spindle regulation,
e.g., ASPM and WDR62. Only
surviving variant and segregates
in family.
PMID:
20427577
and 24875059
11DG0443 microlissencephaly
and global
developmental delay
TUBA3E NM_207312:c.643C >
T:p.R215C
missense tubulin, alpha 3e Mutations in several tubulins have
been linked to lissencephaly and
other cortical malformations (TUBA1
A, TUBA8, TUBB2B, TUBB3, TUBB5,
and TUBG1). Only surviving variant
and segregates in family.
PMID:
24860126
10DG1705 primary microcephaly
and global
developmental delay
INO80 INO80:NM_017553:
c.1501T > C:p.S501P,
INO80:NM_017553:
c.3737G > A:p.R1246Q
missense INO80 complex
subunit E
INO80 has been shown as necessary
for DNA damage repair. Abnormal
DNA damage repair underlies multiple
forms of microcephaly, e.g., PHC1
and PNKP. Supported by a single
linkage peak. Only surviving variant
and segregates in family.
PMID:
21947284,
19829069,
24029917,
and 20118933
08DG00041 hydrocephalus,
muscle weakness
and global
developmental delay
NID1 NM_002508.2:
c.3385+1G > A
splicing
(in-frame
insertion
confirmed
by RT-
PCR)
Nidogen 1 Mice deficient of NID1 exhibit
neurologic deficits including
seizure-like symptoms and loss
of muscle control in the hind
legs and show altered basement
membrane morphology in
selected locations including
brain capillaries and the lens
capsule. Additionally, a variant
of unknown significance has
been reported in a family with
brain malformations. Only surviving
variant and segregates in family.
PMID:
12480912
and 23674478
13DG0167 primary microcephaly
and global
developmental delay
TSEN15 NM_001127394:
c.226T > G:p.W76G
missense tRNA splicing
endonuclease 15
Mutations in other family members,
e.g., TSEN54, have been linked to
pontocerebellar hypoplasia. Only
surviving variant and segregates
in family.
PMID:
18711368
(Continued on next page)
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Table 2. Continued
ID Phenotype Gene Mutation
Mutation
Type Gene Description Supporting Evidence Reference
12DG0929 global developmental
delay, epilepsy and
poor weight gain
DMBX1 NM_147192:c.367C >
T:p.R123W
missense diencephalon/
mesencephalon
homeobox 1
Mouse model displays hyperactivity
and hypophagia. Gene is highly
expressed in developing brain. Only
surviving variant and segregates in
family.
PMID:
15314164
and 17873059
09DG0405 myopathy C2orf63
(CLHC1)
NM_001135598:
c.779G > A:p.R260Q
missense clathrin heavy-
chain linker
domain
containing 1
Mutation in BICD2 which interacts
with CLHC1 causes spinal muscular
atrophy. Only surviving variant and
segregates in family.
PMID:
23664116
09DG00102 global developmental
delay
C12orf4 NM_020374:exon6:
c.637_638insAAAC:
p.K213fs
frameshift chromosome 12
open reading
frame 4
Only surviving variant and
segregates in family.
11DG1513 autism spectrum
disorder
WDR93 NM_020212:c.280T >
C:p.Y94H
missense WD repeat
domain 93
Only surviving variant and
segregates in family.
11DG2479 global developmental
delay and brain
atrophy
ST7 NM_021908:c.489T >
G:p.Y163X
stopgain suppression of
tumorigenicity 7
Disruption of ST7 has been
reported in one ASD patient
with a translocation (t(7;13)
(q31.3;q21)). Only surviving
variant and segregates in family.
PMID:
10889047
12DG1901 holoprosencephaly MATN4 NM_030590:c.515G >
C:p.G172A
missense Matrilin 4 Gene is highly expressed in
developing brain. Only surviving
variant and segregates in family.
PMID:
11549321
12DG2051 intellectual disability
and epilepsy
SEC24D NM_014822:c.697G >
C:p.G233R
missense SEC24 family,
member D
(S. cerevisiae)
Mouse model displays early
embryonic lethality, but the
mouse model of its paralog
SEC24B displays abnormal
neural tube development. Only
surviving variant and segregates
in family.
PMID:
23596517
10DG1069 primary microcephaly
and global
developmental delay
PCDHB4 NM_018938.2:c.915
del:p.K305Nfs*12
frameshift protocadherin
beta 4
PDCHB4 has been associated
with autism. Other protocadherin
members have been linked to
epilepsy, cognitive impairment
as well as autistic features. Only
surviving variant and segregates
in family.
PMID:
22495309
and 22765916
08DG-00322 brain atrophy and
global developmental
delay
PTPN23 NM_015466:c.3995G >
T:p.R1332L
missense protein tyrosine
phosphatase,
nonreceptor
type 23
Mouse model displays early
embryonic lethality. Gene is
highly expressed in developing
brain. Only surviving variant and
segregates in family.
PMID:
19378249
(Continued on next page)
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Table 2. Continued
ID Phenotype Gene Mutation
Mutation
Type Gene Description Supporting Evidence Reference
11DG0932 global developmental
delay and
dysmorphism
TAF6 NM_005641.3:c.212T >
C:p.I71T
missense TAF6 RNA
polymerase II,
TATA box binding
protein (TBP)-
associated factor
Independently identified by another
group (B. Yuan, D. Pehlivan,
E. Karaca, N.P., W.-L. Charng,
T. Gambin, C. Gonzaga-Jauregui,
V.R. Sutton, G. Yesil, S.T. Bozdogan,
T. Tos, A. Koparir, E. Koparir,
C.R. Beck, S. Gu, H. Aslan,
O.O. Yuregir, K. Al Rubeaan,
D. Alnaqeb, M.J.A., Y. Bayram,
M.M. Atik, H. Aydin, B. Geckinli,
M. Seven, H. Ulucan, E. Fenercioglu,
M. Ozen, S. Jhangiani, D.M. Muzny,
E. Boerwinkle, Baylor-Hopkins Center
for Mendelian Genomics, B. Tuysuz,
F.S.A., R.A. Gibbs, and J.R. Lupski,
unpublished data). Only surviving
variant and segregates in family.
10DG1670 global developmental
delay, epilepsy,
dysmorphism,
hypotonia, and VSD
TBCK NM_033115:
c.1708+1G > A
splicing
(frameshift)
TBC1 domain
containing kinase
TBCK knockdown significantly
suppresses mTOR signaling,
which plays a critical role in
multiple neurological disorders.
Only surviving variant and
segregates in family.
PMID:
23977024,
19963289
13DG1472 macrocephaly, ID,
dolichocephaly,
and mild obesity
FAM177A1 NM_001079519:c.297_
298insA:p.L99fs
frameshift family with
sequence
similarity 177,
member A1
Only surviving variant and
segregates in family.
13DG1900 Dandy-Walker
malformation,
hydrocephalus,
flexed deformity,
club feet,
micrognathia,
and pleural effusion
KIAA1109 NM_015312.3:c.1557T >
A:p.Y519*
stopgain KIAA1109 Deletion in Drosophila results
in lethality, and the rare
homozygous flies that reach
adulthood exhibit severe
neurological signs: seizures
and inability to walk or stand
for prolonged period. Only
surviving variant and segregates
in family.
PMID:
19640479
10DG0264 neurodegeneration
and brain iron
accumulation
MTSS1L NM_138383:c.1790C >
T:p.T597M
missense metastasis
suppressor
1-like
This mutation affects a poorly
characterized isoform of VAC14
deficiency of which in mouse
results in severe neurodegeneration.
Only surviving variant and
segregates in family.
PMID:
17956977
(Continued on next page)
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Table 2. Continued
ID Phenotype Gene Mutation
Mutation
Type Gene Description Supporting Evidence Reference
13DG1935 primary microcephaly XIRP1 NM_194293:c.4495G >
A:p.E1499K
missense xin actin-binding
repeat
containing 1
Gene is highly expressed in the
brain in response to oxidative
stress. Only surviving variant and
segregates in family.
PMID:
22366181
13DG2274 severe psychomotor
retardation, seizure,
and cerebellar
hypoplasia
KCTD3 NM_016121:c.1036_
1073 del:p.P346Tfs*4
frameshift potassium
channel
tetramerization
domain
containing 3
Gene is enriched in copy number
changes associated with intellectual
disability. Supported by a single
linkage peak. Only surviving variant
and segregates in family.
PMID:
19623214
13DG0832 global developmental
delay and ADHD
CHAF1B NM_005441:c.496A >
G:p.I166V
missense chromatin
assembly
factor 1,
subunit B
CHAF1B is part of the chromatin
assembly complex deficiency of
which results in loss of asymmetry
during nervous system development
in C. elegans. Only surviving variant
and segregates in family.
PMID:
22177093
08DGRC00077 neurodegenerative
disease
ARV1 NM_022786:c.565G >
A:p.G189R
missense ARV1 homolog
(S. cerevisiae)
ARV1 is required for normal
sphingolipid metabolism, a
process known to be defective
in other neurodegenerative
diseases such as Nieman-Pick
disease. Only surviving variant
and segregates in family.
PMID:
12145310
14DG0152 neurodegeneration
with marked white
matter changes with
high lactate peak in
the brain, consistent
with mitochondrial
encephalopathy
ISCA2 NM_194279:c.229G >
A:p.G77S
missense iron-sulfur
cluster
assembly 2
homolog
Maps to the only shared haplotype
in the extended family. ISCA2 is a
member of mitochondrial iron-sulfur
cluster (ISC) assembly machinery.
Depletion of ISCA2 results in
massively swollen mitochondria that
are devoid of cristae membranes
indicating that it is required for normal
mitochondrial biogenesis. Same
mutation was identified in other
families with identical presentation
(Z.N.A.-H., M. Al-Dosary, M. Alfadhel,
E.F., M. Alsagob, R. Kenana,
R. Almas, O.S. Al-Harazi, H. Al-Hindi,
O.I. Malibari, F.B. Almutari,
T. Al-Sheddi, S. Tulbah, F. Alhadeq,
R. Alamro, A, AlAsmari, M. Almuntashri,
H. Alshaalan, F.A. Al-Mohanna, D. Colak,
N.K., unpublished data). Only surviving
variant and segregates in family.
PMID:
22323289
(Continued on next page)
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ID Phenotype Gene Mutation
Mutation
Type Gene Description Supporting Evidence Reference
13DG0215 global developmental
delay, hearing loss,
and ataxia
PTRH2 NM_016077.3:c.254A >
C:p.Q85P
missense peptidyl-tRNA
hydrolase 2
Null mice show ataxia and weakness;
tissue examination revealed delayed
development. Only surviving variant
and segregates in family.
PMID:
18218778
08DG0048510DG070313DG1542 (08DG00485) global
developmental delay,
severe dystonia, and
congenital cataract
(10DG0703) global
developmental
delay and congenital
cataract(13DG1542)
global developmental
delay, congenital
cataract, tubulopathy,
and severe osteopenia
GEMIN4 NM_015721:c.2452T >
C:p.W818R
missense gem (nuclear
organelle)
associated
protein 4
Maps to the only shared haplotype
in the three families. GEMIN4 is part
of the SMN complex, and reduced
SMN protein results in spinal
muscular atrophy. Supported by a
single linkage peak. Only surviving
variant and segregates in family.
PMID:
11914277
13DG1549 intellectual disability
and epilepsy
MYOCD NM_001146312:
c.1252A > G:p.I418V
missense myocardin Only surviving variant and segregates
in family.
PMID:
12867591
13DG0274 global developmental
delay, typical
Joubert syndrome,
MRI findings
PDPR NM_017990:c.1360G >
T:p.G454C
missense pyruvate
dehydrogenase
phosphatase
regulatory
subunit
Only surviving variant and segregates
in family.
10DG0934 cerebellar vermis
hypoplasia, Dandy-
Walker malformation,
hydrocephalus,
developmental delay
DPH1 NM_001383.3:c.701T >
C:p.L234P
missense diphthamide
biosynthesis 1
Diphthamide is a unique
posttranslationally modified
histidine found only in translation
elongation factor-2 (eEF2), which
is linked to spinocerebellar ataxia.
Diphthamide modification of eEF2
is essential for normal mouse
development. Only surviving variant
and segregates in family.
PMID:
18765564
11DG0417 global developmental
delay, light
complexion, early
onset focal segmental
glomerulosclerosis
NUP107 NM_020401:c.303G >
A:p.M101I
splice site nucleoporin
107 kDa
Only surviving variant and segregates
in family.
14DG0221 cerebellar atrophy,
hydrocephalus, and
global developmental
(cognitive, speech,
and motor) delay
TMEM92 NM_001168215:
c.95+3A > G
splice site transmembrane
protein 92
Only surviving variant and segregates
in family.
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Cyield. In 2011, Najmabadi et al. reported the identification of 50
novel candidate genes (Najmabadi et al., 2011). Although that
study, similar to ours, combines autozygosity mapping with
next-generation sequencing of candidate ROH, their cohort
was not enriched for novel gene discovery. Consequently, there
were numerous cases that, upon exome sequencing, identified a
gene that was classically linked to the clinical presentation (as
per their Table 1). More importantly, the pipeline used in that
study did not strictly require that the candidate variant be the
only one to survive filtering in that family; hence, 24 of their candi-
date genes (48%) were not the sole surviving variant. Of the
remainder, one variant (HIST3H3) is present at sufficiently high
frequency in our collection of 485 exomes to be excluded (allele
frequency 0.0082).
Beyond our analytic pipeline, the candidacy of many of our
candidate genes can be corroborated through other lines of
evidence. In the case of INO80, KCTD3, GEMIN4, and ISCA2,
each of these genes maps to the only shared haplotype
genome-wide across multiple or extended multiplex families
(Figure S3). TUBA3E belongs to a family of proteins that are
known to be involved in brain malformation syndromes including
lissencephaly, which is present in the affected patient (Figure S4)
(Jaglin et al., 2009; Keays et al., 2007; Poirier et al., 2010). As
well, TSEN15 belongs to a family of proteins (t-RNA splicing en-
donucleases) that have been foundmutated in patients with pon-
tocerebellar hypoplasia and microcephaly, which is what we
observed in our patient (Budde et al., 2008; Cassandrini et al.,
2010; Namavar et al., 2011). SPDL1 controls poleward move-
ment of chromosomes along the mitotic spindles, analogous to
many of the known primarymicrocephaly genes that are involved
in mitotic spindle regulation (Barisic et al., 2010; Chen et al.,
2014); our patient exhibits an extreme reduction in overall brain
volume resulting in an almost empty skull (Figure S4). ISCA2 is
involved in mitochondrial protein maturation, and depletion of
the protein results in massively swollen mitochondria that are
devoid of cristaemembranes (Sheftel et al., 2012). This is consis-
tent with the mitochondrial encephalopathy detected in our
patient. Table 2 summarizes what is known of the 33 candidate
genes and available evidence that supports candidacy.
We were unable to identify a causal mutation in 25.9% of
cases. Many of these have two or more variants that remained
after filtering (Table S1), leaving open the possibility that one of
these surviving variants may indeed be causal. Some of these
are strong candidates. For instance, case 11DG0375 with brain
atrophy has the first reported null mutation in SNCG, which en-
codes synuclein-g, and, although a role in neurodegeneration
has been suspected, such a role has remained elusive (Greten-
Harrison et al., 2010). Similarly, TRIM4 is a member of a family
of proteins that has been implicated in a number of neurological
disorders (TRIM2 in Charcot-Marie-Tooth, TRIM32 in Limb-Gir-
dle Muscular Dystrophy, and TRIM18 in Opitz-GBBB (a syn-
dromic form of intellectual disability) (Balastik et al., 2008; Frosk
et al., 2002; Quaderi et al., 1997). Thus, the homozygous TRIM4
truncation we identified in 12DG2083 may prove causal if addi-
tional mutations in this gene are identified in the future.
Cases in which no variants survived our filters may harbor
classes of mutations that either the sequencing technology
or our analysis pipeline are biased against e.g., compoundell Reports 10, 148–161, January 13, 2015 ª2015 The Authors 157
Figure 1. Pedigrees of Families with Novel Candidate Genes following WES Analysis
The family ID is presented above each pedigree. A red box indicates the affected family member who was submitted for WES, and asterisks denote all the family
members we had access to for confirming segregation.heterozygous mutations, X-linked mutations, or mutations
involving introns, UTRs, regulatory elements, and repeats. None-
theless, our study clearly shows the utility of our approach when
applied in the right population. Our pipeline as mentioned here
has been very successful historically. Many unpublished genes
we highlighted as novel and disease causing at the time of
data analysis were subsequently published and verified by
others, and this lends weight to the candidacy of the genes we
report here. Indeed, such reports appeared as recently as a
few months from this submission, e.g., DIAPH1, PIGQ, and
WWOX (Ercan-Sencicek et al., 2014; Mallaret et al., 2014; Martin
et al., 2014). This is also true for certain variants in ‘‘unsolved’’
cases where more than one variant remained, e.g., SLC13A5
(Thevenon et al., 2014). Our aim in publishing these 33 candidate
genes is to accelerate the discovery of other independent muta-
tions, thereby confirming pathogenicity and assisting in genetic
diagnosis. Scaling of our study is feasible given the availability
of the appropriate patient samples and the dropping cost of
sequencing technology, with the promise that all autosomal158 Cell Reports 10, 148–161, January 13, 2015 ª2015 The Authorsrecessive neurogenetic disease genes can be mapped within
the timeframe required by the global brain initiatives.
EXPERIMENTAL PROCEDURES
Human Subjects
Consanguineous families with history of a neurological disorder were clinically
evaluated and recruited for this study using a King Faisal Specialist Hospital
and Research Center institutional-review-board-approved protocol (RAC#
2121053) with informed consent. All families were multiplex, and all parents
were confirmed to be healthy. Pedigrees of families with the 33 candidate
genes are given in Figure 1. For each family, blood was collected in EDTA
tubes from all available members, and families were only included if at least
one affected individual was available for sampling. DNA was extracted from
whole blood using standard protocols.
Autozygome-Guided Mutation Analysis
Genome-wide SNP genotyping and homozygosity mapping was performed
using the AxiomGWHSNPChip platform (Affymetrix). See Supplemental Infor-
mation for more details. Genes known to cause a neurological disorder
compatible with the patients’ phenotype, and present within the autozygome,
Autozygome-guided 
sequencing of known 
disease genes 
is negative
n=143 families
Intellectual 
Disability
Ausm
Global 
developmental 
delay
Primary 
Microcephaly/
Brain 
malformaons
EpilepsyAtaxia
Unsolved: no 
remaining 
variants  (27)
Solved cases
(105)
Unsolved: >2 
remaining 
variants (10)
A  Recruitment
B  Enrichment step  WES
D  Data ﬁltraon and results
C
Figure 2. Schematic of the Experimental
Pipeline for This Study
A total of 143 multiplex consanguineous families
with history of a neurological disorder were
found negative for known disease genes following
autozygome-guided analysis and were recruited
for this study. The bar illustrates the breakdown
based on the number of cases, whereas the pie
chart is based on the number of distinct genes
identified in the solved cases.were screened by PCR and Sanger sequencing. If no such genes existed, or
if they did exist but were excluded by sequencing, exome capture was per-
formed. In total, individuals from 143 families were exome sequenced, and
these families formed the cohort for this study.
Exome Sequencing
Exome capture was performed using the TruSeq Exome Enrichment kit
(Illumina). See Supplemental Information for more details. A summary of the
quality control data for exome sequencing is provided in Table S2.
Analysis of Exomic Variants
Exome-derived data were filtered according to the schematic in Figure 2.
See Supplemental Information for full details. Segregation was assessed for
all surviving variants, using all family members we had access to (Figure 1).
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